Vertex Pharmaceuticals (VRTX) Other Operating Expenses (2009 - 2026)

Vertex Pharmaceuticals' Other Operating Expenses history runs 18 years deep, the most recent figure standing at $393.5 million for Q1 2026.

• In Q1 2026, Other Operating Expenses fell 48.49% year-over-year to $393.5 million; the TTM figure through Mar 2026 stood at $1.8 billion (down 72.4% YoY), while the FY2025 annual figure was $2.2 billion, down 64.84% from the prior year.
• Other Operating Expenses for Q1 2026 stood at $393.5 million, down from $523.4 million in the prior quarter.
• The five-year high for Other Operating Expenses was $4.8 billion in Q2 2024, with the low at $240.3 million in Q1 2022.
• The 5-year median for Other Operating Expenses is $410.6 million (2025), against an average of $682.0 million.
• The sharpest annual moves came in 2024 and 2025: Other Operating Expenses surged 1052.09% in 2024, then tumbled 91.48% in 2025.
• Vertex Pharmaceuticals' Other Operating Expenses stood at $307.7 million in 2022, then grew by 9.03% to $335.5 million in 2023, then surged by 51.92% to $509.7 million in 2024, then grew by 2.69% to $523.4 million in 2025, then decreased by 24.82% to $393.5 million in 2026.
• Business Quant data shows VRTX's Other Operating Expenses at $393.5 million in Q1 2026, $523.4 million in Q4 2025, and $467.4 million in Q3 2025.